Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT0EOB8)

• DTT Name: B-Raf messenger RNA (BRAF mRNA) DTT Info
• Gene Name: BRAF

Molecule-Related Drug & Molecule List

4 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MLN2480	DMBR8NF	Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
PLX-4720	DMBK9AM	Cutaneous melanoma	2C30	Phase 1	[2]
RG7304	DMGFAVQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
SPN-803	DM8O2AQ	Parkinson disease	8A00.0	Phase 1	[1]

13 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-(Benzylamino)-6-(3-acetamidophenyl)pyrazine	DM4X6I9	Discovery agent	N.A.	Investigative	[4]
2-(Phenylamino)-6-(3-acetamidophenyl)pyrazine	DMPUARE	Discovery agent	N.A.	Investigative	[4]
ISIS 13727	DMCDW4H	Discovery agent	N.A.	Investigative	[5]
ISIS 13730	DMRJBH4	Discovery agent	N.A.	Investigative	[5]
ISIS 13740	DM5Q12D	Discovery agent	N.A.	Investigative	[5]
ISIS 13741	DMC7Q38	Discovery agent	N.A.	Investigative	[5]
ISIS 13743	DMO6R1I	Discovery agent	N.A.	Investigative	[5]
ISIS 14144	DMWIKD5	Discovery agent	N.A.	Investigative	[5]
L-779450	DM51B74	Discovery agent	N.A.	Investigative	[6]
PLX-ORI3	DMZG1L5	Solid tumour/cancer	2A00-2F9Z	Investigative	[1]
PMID26061392C2	DMHZOIU	Discovery agent	N.A.	Investigative	[7]
Pyrazolo[1,5-a]pyrimidine-3-carboxylate	DM69LKB	Discovery agent	N.A.	Investigative	[8]
ZM-336372	DMD5JYQ	Discovery agent	N.A.	Investigative	[9]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943).
• [2] Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
• [3] Clinical pipeline report, company report or official report of Roche.
• [4] Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem. 2006 Jan 12;49(1):407-16.
• [5] US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression.
• [6] The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
• [7] Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib. ACS Chem Biol. 2015 Sep 18;10(9):2099-107.
• [8] Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2735-8.
• [9] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.